Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.
about
Antiretroviral resistance testing in treatment-naive HIV-infected adultsAntiretroviral resistance testing in treatment-naive HIV-infected adultsCirculating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activitiesComparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptaseAnalysis of HIV-1 drug resistant mutations by line probe assay and direct sequencing in a cohort of therapy naive HIV-1 infected Italian patientsA mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavirSelection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thio-5-fluorocytidineThe polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistanceA randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: the CREST studyPatient and regimen characteristics associated with self-reported nonadherence to antiretroviral therapyPyrosequencing dried blood spots reveals differences in HIV drug resistance between treatment naïve and experienced patientsIncidence and associated factors of HIV drug resistance in Chinese HIV-infected patients receiving antiretroviral treatmentHIV-1 pol diversity among female bar and hotel workers in Northern TanzaniaHIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based SchemesCombinatorial approaches to the prevention and treatment of HIV-1 infectionCombining cross-sectional and prospective data methods to improve transition parameter estimation for characterizing the accumulation of HIV-1 drug resistance mutations.The tolerability of efavirenz after nevirapine-related adverse events.Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy.Frequency of Drug-Resistant Variants of HIV-1 Coexistent With Wild-Type in Treatment-Naive Patients of IndiaBritish HIV Association guidelines for prescribing antiretroviral therapy in pregnancy (1998).Pharmacologic considerations for therapeutic success with antiretroviral agents.Utilization of medical treatments and adherence to antiretroviral therapy among HIV-positive adults with histories of childhood sexual abuse.Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activitiesHuman immunodeficiency virus drug resistance testing: state of the art in genotypic and phenotypic testing of antiretrovirals.Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture.Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy.Antiretroviral resistance during successful therapy of HIV type 1 infection.Management of the adverse effects of antiretroviral therapy and medication adherence.Human immunodeficiency virus type 1 group m protease in cameroon: genetic diversity and protease inhibitor mutational featuresHuman immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing.Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing.Performance of the applied biosystems ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for sequence-based analysis of HIV-1 in pediatric plasma samples.Human immunodeficiency virus type 1 drug resistance testing: a comparison of three sequence-based methods.Recovery and analysis of human immunodeficiency virus type 1 (HIV) RNA sequences from plasma samples with low HIV RNA levels.Sequence diversity of the reverse transcriptase of human immunodeficiency virus type 1 from untreated Brazilian individuals.A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1A bacteriophage lambda-based genetic screen for characterization of the activity and phenotype of the human immunodeficiency virus type 1 proteaseHuman immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapyRapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5)
P2860
Q24198919-62C7952A-BB4B-46A3-8430-73788563ACBCQ24240372-63F0B0D9-082E-4EDE-9A5D-6C4F22F7CE30Q24550608-8FB72624-28D4-4BD5-BF73-AB5637B4C143Q24550959-CA713DF4-0D1F-47D3-AE5E-58155864EC9DQ24795766-66D9CB9C-E3C6-4C96-A2B1-EEA17B3940D4Q28344112-A4EC31FD-8395-407A-B37E-9B5F817E0667Q28344137-736201E7-1EDB-4DD8-95BA-FD89183CB2AAQ28350136-A1A32C7C-AF3D-459E-A74F-348F4E2B10E3Q28469027-28EE5BA4-A8C9-4C4E-880A-E30D569B8B89Q28469228-FCAD9DA0-96AF-40AA-8D09-5E8723DADE75Q28486033-09F2B4B8-7D16-4683-9723-066F1426988FQ28487377-95092421-BD5C-448C-B6FC-03800DB043A0Q28540536-CA48573C-F2AA-4CEB-B134-C4813517BF4DQ28551618-48704E5E-B2AB-4910-81C7-CBA81128EFACQ30400060-37C53CCF-7803-4772-9B43-3D02B618EDDBQ31107886-942F0A6B-4D92-4159-A615-95CFAF05FB53Q31444144-99E6CE73-F446-45A2-BD17-B583295AC90CQ31913462-7A407B23-6805-4575-9355-A64661809BFCQ33583299-7E0503DA-01A1-4B86-8582-2448732907E0Q33711667-00C745DA-56B6-47F2-8C27-18204CE78FCFQ33735400-432F236F-EDC4-4522-89A6-7FAD84389E56Q33796937-A3D66FE8-756F-423A-92F1-33EBDB51426EQ33797464-283D4CB5-7DF4-4504-AD76-B3195CEAD0E2Q33815628-EA5A12C7-048A-449A-A939-6967B6612417Q33839756-9FFE8548-C214-4E13-BC7A-12F053CEFED3Q33873983-AE34AE0A-67F6-4079-9B23-5D99F5E4524EQ33894498-D0C4C3F2-6D4D-449A-A0B1-9191DC292662Q33919308-AE1A645B-E29B-4207-ABB2-DDCA5A832A3BQ33946887-912036ED-0351-489A-8312-9182FEF76C2FQ33951471-49F3D9F3-FF21-4E36-BBFE-1659254D9DDCQ33962513-027625FF-FA82-4A39-AEF6-162819451412Q33971117-C02251B1-E234-4054-9B75-12F1C1C90060Q33971776-1C8D6F71-878F-475D-82F3-ECB4BDA2852AQ33972550-84410EF4-856E-4B62-8925-3D3A3BD411A9Q33974840-EA074AA4-5BB5-4D0A-9F98-AC7FD3A372D9Q33977153-6BE16D7A-010D-4579-A56C-A63434353A3CQ33979107-CB3B5977-47E7-46BD-9474-A40AC8F8AC0CQ33979321-B11FC1A1-82B6-490F-9B05-76CAB8392AEBQ33980528-B707A2E9-6C56-4D77-9A79-FDBCE4A50F25Q33981401-FCFFD9B5-E95C-4FE1-9DAE-B3A1E4999030
P2860
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Antiretroviral drug resistance ...... ional AIDS Society--USA Panel.
@en
Antiretroviral drug resistance ...... ional AIDS Society--USA Panel.
@nl
type
label
Antiretroviral drug resistance ...... ional AIDS Society--USA Panel.
@en
Antiretroviral drug resistance ...... ional AIDS Society--USA Panel.
@nl
prefLabel
Antiretroviral drug resistance ...... ional AIDS Society--USA Panel.
@en
Antiretroviral drug resistance ...... ional AIDS Society--USA Panel.
@nl
P2093
P356
P1476
Antiretroviral drug resistance ...... tional AIDS Society--USA Panel
@en
P2093
D D Richman
D M Jacobsen
D R Kuritzkes
F Brun-Vézinet
J W Mellors
L M Demeter
M S Hirsch
P304
P356
10.1001/JAMA.279.24.1984
P407
P577
1998-06-01T00:00:00Z